New Double-Action drug tested for tough blood cancer
NCT ID NCT05216835
Summary
This early-stage study tested a new drug called sabestomig (AZD7789) in adults and young adults whose Hodgkin lymphoma had returned or did not respond to at least two prior treatments. The main goals were to find a safe dose and see how the body processes the drug. The drug is designed to work by targeting two specific proteins on cancer cells to help the immune system fight the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Duarte, California, 91010, United States
-
Research Site
Miami, Florida, 33136, United States
-
Research Site
Rochester, Minnesota, 55905, United States
-
Research Site
New York, New York, 10065, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Toronto, Ontario, M5G 1X6, Canada
-
Research Site
Montreal, Quebec, H3T 1E2, Canada
-
Research Site
København Ø, 2100, Denmark
-
Research Site
Lille, 59037, France
-
Research Site
Bologna, 40138, Italy
-
Research Site
Naples, 80131, Italy
-
Research Site
Valencia, 46010, Spain
-
Research Site
Manchester, M20 4BX, United Kingdom
-
Research Site
Oxford, 0X3 7LJ, United Kingdom
Conditions
Explore the condition pages connected to this study.